Immunization Station

Age	Immunization
2 months	**Vaxelis (DTaP-IPV/HepB/Hib)**, **Vaxneuvance (PCV15)**, **RotaTeq (RV5)**
4 months	**Vaxelis (DTaP-IPV/HepB/Hib)**, **Vaxneuvance (PCV15)**, **RotaTeq (RV5)**
6 months	**Vaxelis (DTaP-IPV/HepB/Hib)**, **Vaxneuvance (PCV15)**, **RotaTeq (RV5)**, **flu (eligible)**
12 months	**M-M-R II**, **Varivax (Varicella)**, **Vaqta (Hep A)**
15 months	**Vaxneuvance (PCV15)**, **Pentacel (DTaP-IPV/Hib)**
18 months	**Vaqta (Hep A)**
4 years	**ProQuad (MMR & Varicella)**, **Quadracel (DTaP-IPV)**
11 years	**Adacel (Tdap)**, **Menquadfi (ACWY)**, **Gardasil (HPV)**
16 years	**Menquadfi (ACWY)**, **Trumenba (Meningococcal B)**

Adacel (Tdap)

- **Number of doses:** 1 dose (booster) at 11–12 years old, then every 10 years.
- **Spacing:**
  - Administer at least 5 years after the last tetanus-containing vaccine.
- **Major teaching:**
  - Protects against tetanus, diphtheria, and pertussis.
  - Critical for adolescents and adults to prevent pertussis transmission to infants.
  - May cause mild pain or swelling at the injection site.

Gardasil (HPV)

- **Number of doses:**
  - 2 doses (6–12 months apart) for individuals starting at age 11–12 and under 15 years.
  - 3 doses (0, 1–2, and 6 months) for individuals ≥15 years or immunocompromised.
- **Spacing:**
  - Ensure a minimum interval of 5 months between the first and last doses.
- **Major teaching:**
  - Protects against HPV-related cancers and genital warts.
  - Most effective when given before exposure to HPV.
  - May cause fainting; observe adolescents for 15 minutes post-vaccination.

M-M-R II (Measles, Mumps, Rubella)

- **Number of doses:** 2 doses (at 12–15 months and 4–6 years).
- **Spacing:**
  - Minimum interval: 4 weeks between doses.
- **Major teaching:**
  - Live vaccine; avoid in immunocompromised individuals or during pregnancy.
  - May cause mild fever or rash 1–2 weeks after vaccination.
  - Critical for preventing measles outbreaks.

Menquadfi (Meningococcal ACWY)

- **Number of doses:** 2 doses (at 11–12 years and 16 years).
- **Spacing:**
  - At least 8 weeks between doses if additional doses are required for high-risk individuals.
- **Major teaching:**
  - Protects against meningococcal disease (ACWY serogroups).
  - Recommended for college students living in dormitories.

- May cause mild soreness at the injection site.

Pentacel (DTaP-IPV/Hib)

- **Number of doses:** 4 doses (at 2, 4, 6, and 15–18 months).
- **Spacing:**
  - Minimum interval of 4 weeks between doses in the primary series (2, 4, and 6 months).
  - Booster dose at 15–18 months, spaced at least 6 months after the third dose.
- **Major teaching:**
  - Combines protection against 5 diseases: diphtheria, tetanus, pertussis, polio, and *Haemophilus influenzae* type b (Hib).
  - Reduces the number of injections needed at each visit.
  - Common side effects include mild fever, irritability, and injection site redness/swelling.
  - Ensure parents are aware of the importance of completing the series for full protection against these diseases.

ProQuad (MMR & Varicella)

- **Number of doses:** 2 doses (at 4–6 years and earlier if needed).
- **Spacing:**
  - Minimum interval of 3 months between doses.
- **Major teaching:**
  - Combines MMR and Varicella for convenience.
  - Live vaccine; avoid in pregnancy or severe immunosuppression.
  - Mild rash or fever may occur.

Quadracel (DTaP-IPV)

- **Number of doses:** 1 dose at 4–6 years.
- **Spacing:**
  - Must be spaced at least 6 months after the previous DTaP-IPV dose.
- **Major teaching:**
  - Protects against diphtheria, tetanus, pertussis, and polio.
  - Booster dose completes the series before entering school.

RotaTeq (RV5)

- **Number of doses:** 3 doses (at 2, 4, and 6 months).
- **Spacing:**
  - Minimum interval of 4 weeks between doses.
  - Final dose must be administered before 8 months of age.
- **Major teaching:**
  - Protects against severe rotavirus gastroenteritis.
  - Oral vaccine; no injection required.
  - Common side effects include mild diarrhea or fussiness.

Trumenba (Meningococcal B)

- **Number of doses:** 2 doses (0 and 6 months apart).
- **Spacing:**
  - A 3-dose schedule (0, 1–2, and 6 months) may be recommended for certain high-risk groups.
- **Major teaching:**
  - Protects against meningococcal B disease, which can cause rapid and severe infections.
  - Recommended for individuals 16–23 years old, especially those in high-risk settings (e.g., college campuses).

Vaqta (Hep A)

- **Number of doses:** 2 doses (at 12 months and 18 months).
- **Spacing:**
  - At least 6 months between doses.
- **Major teaching:**
  - Protects against hepatitis A, a liver infection spread by contaminated food/water.
  - Common side effects include mild injection site soreness.

Varivax (Varicella)

- **Number of doses:** 2 doses (at 12–15 months and 4–6 years).
- **Spacing:**
  - Minimum interval of 3 months between doses.
- **Major teaching:**
  - Live vaccine; avoid in pregnancy or severe immunosuppression.
  - Mild rash or fever may occur 1–2 weeks after vaccination.

Vaxelis (DTaP-IPV/HepB/Hib)

- **Number of doses:** 3 doses (at 2, 4, and 6 months).
- **Spacing:**
  - Minimum interval of 4 weeks between doses.
- **Major teaching:**
  - Protects against six diseases (diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b).
  - May cause mild fever, soreness, or swelling at the injection site.

Vaxneuvance (PCV15)

- **Number of doses:** 4 doses (at 2, 4, 6, and 15 months).
- **Spacing:**
  - Minimum interval of 4 weeks between primary doses.
  - Booster dose recommended at least 8 weeks after the 3rd dose.
- **Major teaching:**
  - Protects against 15 serotypes of *Streptococcus pneumoniae*, which can cause pneumonia, meningitis, and bacteremia.
  - May cause mild fever or irritability post-vaccination.

Flu Vaccine

FluMist (Live Attenuated Influenza Vaccine - LAIV4)

- **Type:** Live attenuated vaccine administered intranasally.
- **Age indications:** Approved for healthy individuals aged 2–49 years.
- **Effectiveness:** Comparable to the flu shot in most years but may vary depending on the season and strains.
- **Contraindications:**
  - Children <2 years or adults ≥50 years.
  - Pregnant individuals.
  - Immunocompromised individuals or close contacts of severely immunocompromised individuals (e.g., bone marrow transplant patients in protective isolation).
  - Children 2–4 years with asthma or wheezing in the past 12 months.
  - Severe allergy to any FluMist component.
- **Major teaching:**
  - Avoid in individuals taking aspirin or salicylate-containing medications due to the risk of Reye's syndrome.
  - Mild side effects include runny nose, sore throat, or headache.

Flu Shot (Inactivated Influenza Vaccine - IIV4)

- **Type:** Inactivated vaccine administered via intramuscular injection.
- **Age indications:** Approved for individuals 6 months and older, including pregnant individuals and those with chronic health conditions.
- **Effectiveness:** Provides broad protection against circulating influenza strains; updated yearly to match predicted strains.
- **Contraindications:**
  - Severe allergy to any flu shot component, including egg protein (though egg-free formulations are available).
- **Major teaching:**
  - Common side effects include mild soreness or swelling at the injection site, low-grade fever, or fatigue.
  - Safe for individuals with chronic medical conditions or weakened immune systems.
  - For children <9 years receiving the flu vaccine for the first time, 2 doses are required at least 4 weeks apart.

Key Differences:

Aspect	FluMist (Nasal Spray)	Flu Shot (Injection)
Type of Vaccine	Live attenuated	Inactivated
Route of Administration	Nasal spray	Intramuscular injection
Age Range	2–49 years	6 months and older
Pregnancy Safe?	No	Yes

Aspect	FluMist (Nasal Spray)	Flu Shot (Injection)
Immunocompromised Use?	No	Yes
Common Side Effects	Runny nose, sore throat, headache	Soreness, redness, low-grade fever

---

Revision #7
Created 2025-01-25 06:25:55 UTC by Josh LeJeune NP
Updated 2025-01-27 01:14:34 UTC by Josh LeJeune NP